Amgen Options Flip Bullish as Biotech Peers Rally Into Earnings

AMGN trades near $465, up 4.7% on the week, roughly in line with the median gain of 4.1% across its closest large-cap biotech peers. GILD and VRTX ran harder, adding 9.4% and 6.7% respectively, while BIIB lagged at 1.2%. Within that context, Amgen's move looks measured rather than stretched.

Options positioning has flipped notably toward the bullish end of its recent range heading into tonight's print. The put/call ratio dropped to 0.86, more than two standard deviations below its 20-day average of 0.99. That is among the most call-heavy readings of the past year, with the PCR's 52-week low at 0.63 providing the only lower bound. The shift is recent and sharp: throughout September and into mid-October, the ratio sat consistently above 1.0, reflecting a dominant preference for downside protection. Since then, calls have taken over as the stock has climbed 15% over the past month to close near $465.

The analyst community is split almost evenly on what that move has bought. Oppenheimer lifted its target to $480 last week, keeping an Outperform rating, while UBS went to $470 with a Buy. Against those, Barclays sits at $400 on an Equal-Weight, Morgan Stanley at $359, and the consensus mean target of $397 now sits roughly 15% below the current price. The bull case rests on six key growth drivers that grew 26% year-on-year in the second quarter, accounting for nearly 70% of product sales, with Repatha, Imdelltra and Tezspire all scaling globally. Bears point to mixed script trends in recent months, a negative readout on pelacarsen that clouded the cardiovascular pipeline, and a revenue and EPS estimate for the third quarter that the bear model places below Street consensus.

Short interest is modest and offers no real signal here. At 2.4% of free float, it has been broadly stable for weeks. Borrow availability is extremely loose, with roughly 536 million shares available against 13 million short. That removes any squeeze dynamic from the equation: the positioning story belongs entirely to options and price action, not the lending market.

The print will test whether Amgen's commercial momentum in the third quarter is enough to support a stock now trading above the majority of analyst targets, or whether the gap between price and consensus forces a recalibration.